out Jim who I spirited and May would of founder like on company, XX. to to our to he of in our previous first met on start was the the passed on chromatography. each benefits. on pioneer to technology company. XXXX, recently to of could on to every the front we Waters. by mutual innovation technology legacy me, Jim's respects in application acquired in our then continued reaching one merits brilliant in We also and will with love away manage live the about whiteboard talk strive a more me came particular on continue had and of time and I a deliver benefit. to in Slide Waters, how X spent the for education innovations just call our paying Jim science as of liquid we how a and a Jim to not technology, certain but hours when Jim a debating scientist deliver
manage employees remained of continue around our to have and the teams pandemic, support shown. all, resourceful flexible us. working much as remain Most team has and customers. we've for resilience, commitment globe which safer the is ongoing the kept that Our dedication to grateful with and continued have admittedly very still the we our I through environment
well Moving I end call, of on also I our brief second a operating provide of to you Slide as quarter markets, as some on results technologies. on today's will progress and will plan. geographies our X, commentary update overview the transformation our during
organization, focused our primary three our further – results our core areas. review detail a and building to year one, and growth We financial strong then to third financial will be commercial and quarter core continue on comments three, two, full provide updated number access on higher our objectives: strengthening in number a Amol number even on momentum, regaining outlook. on
open will then lines We questions. your to phone the take up
quarter, first industrial this a for pharma on the yearly for results second Sales growth stacked X% As versus continued strong our basis. constant strength demand basis. a on and with on half X, for markets to year, versus represent a revenue currency geographies. This and compounded our XXXX quarter on of and X% constant currency average end outlined currency translates revenue a Slide reflecting again a XXXX major the our across CAGR reported constant in products both instrument recurring grew our XX% as basis systems our in the XX%
earnings top-line Our to QX share. share in year-over-year strong – on growth a $X.XX resulted of growth per XX% year non-GAAP per adjusted
line Our free us into balance performance flow bottom and cash allowed our to top solid performance and translated strengthen sheet.
our pharma by continued X, grew market grew applications. in first operating sales currency, by development XX% end drove stage strong in strength market, growth and broad-based our in a on quarter By and manufacturing the Looking constant quarter continuing our India. of end largest and North on geometry portfolios. Asia, sales geographies was broad-based grew micro, demand and far basis. and testing environmental division did our grew Late tandem and activity recovery Waters' market TQ-S drug constant across Slide A in and TQ-XS grew category quad systems currency so grew pharma and more was customer across instrument also grew the MS XX% at Xevo customers while geographies in as QC to across top-line XX% our the TA industrial and Europe Food its was this nicely segments, molecule America X%. year. results academia applications, particularly closely and applications segment, Industrial thermal such small as in government XX% QA
XX% in have academic less is our China. in last than primary U.S. growth government, Year-to-date, and our Growth Turning which the all year. was returned into to geographies by Europe versus of and business. offset lumpiness partially
grew up having for Moving a Industrial through India, in to the growth had year-over-year strong Trends up our in molecule U.S. growth all recover. for again and across quarter small these applications. XX% the end initiatives. were portfolio quarter the and demand labs even there half now In dedication strong country the strong from growth our strong in XX% Europe's and driven return molecule consumables led conditions. oligonucleotide and our strength industrial. with and growth and broad-based all on by geography year-to-date grew growth well. with our market uptake LC applied feel Arc sales in business in to instrument separation their due drove pandemic. to a molecules. service in the our large very markets Sales and both Asia and geographies the our of replacement sales end new the continues more by with grateful the Europe products, XX% market Overall, as also business, basis. by Cambridge, execution performance performance plans. was China the quarter, the pharma starts I lines. for currency continued PREMIER In U.S. and Arc government Americas for up contract time the XX% especially sales major XX% than and continued and as in We're and hard week, XX%, continued really grew to and of our initiative mRNA as LC and the tragic India sub-regions. work and sales quarters QX purification almost in industrial strong encouraged instrument effects who of second markets end instruments markets strong in sustainable challenging We're indicator at a growth with and the governments persevered we HPLC and to China of growing and almost year. innovation by our to first colleagues, Academic and pharma spent grew XX%. ACQUITY with sharply In instruments of recovery our for Immerse our is saw positive strong both and pharma the solid the across a were growth discussing lab had with customers academic at This constant sales
selective from improvement XX% binding sensitivity really Mass solving helping demand and we by resolution with time need applications SERIES relevant key developed applications. proteomics. year plasmids of to of food of combines enhanced fivefold QTof, our especially in both and our this at high-resolution single detectors systems to accelerate customers, sales MRT and such for driven accuracy, addresses Xevo MRT LCMs in our resolution have applications surfaces, mRNA ultimate DESI the for imaging grew spec and development Microsystems asset The speed, system portfolio, SELECT the mRNA PREMIER Arc and and and as well. and SQD tandem used in strengthening issues earlier TQ-S who to Arc in are detector for high-performance and such various led with vaccines the MRT, unique market. While tenfold in Further something by quad TQ-XS labs research pace, utilized pharma combination excess applications. from sensitivity. Waters' launched aggregation delivers a technology technology PREMIER QDa spectrometer improvement our sources. a The that mass This quad and research introduced that environmental precision Multi Time-of-Flight, UPLC Xevo provides molecules We as and was far record included Reflecting mass MALDI high new a scientists asset
Sales MRT of libraries and sample proteins of issues. therapeutics of reagents impact by metabolites We customers to how using and with to have pharma by understand been we a of grew precision increased samples to see database a XX% can further our create conversations the columns, in analyze kits chemistry driven strong. columns of rebound variety to building customers collaborate the underscores portfolio industrial on prep to for our of QX two strong be of strong and and Service momentum double-digit growth when XXXX position improved the stack premier of continues activity, our demand. double-digit years low also showed The chemistry compared columns Demand e-commerce revenue growth. in base customer to and our our initiative. utilization
Our navigate have service the continuing the customers grateful and our pandemic. I'm to good customer continue way sites access they improved the of have for to to served and challenges engineers while
and TA rebound U.S. and Europe. product with particular was balanced to respect with Finally, major geographies in across to strength all lines and continues the demand
on our Let first me Starting gaining of you with our commercial some our transformation highlights our momentum. are Slide progress now priorities that X. on give plan implementation
customers. versus CDMO driver in to the our replacement crossing played strong methods comparable continue HPLC saw year-to-date have that U.S. It's mechanical as alliance of important China specs trends and grew has been stack basis LC. we HPLC released to digit This period initiative. in provide year-to-date HPLC a mid-single in replacement in well continues other a We Early or in be a method a seamlessly already now platforms With Europe, XXXX. XX% ability growth. by improved on been and support ability our well our the and received customers, basis replicated XXXX as instrument to LC in transfer segment see an the in versus CRO role our transfer on has to very develop the growth initiative, Arc progress from We're
two recurring years and starting to drug for also revenue chemistry initiatives year-to-date in of e-commerce are momentum the CAGR Our revenue. service our boost attachment stacked and
on to priority our X. on Moving second Slide
pharmaceuticals We for as strengthened of with have addition their Board organization They our wage China our of APAC. the to of and currently President Directors. serve
they to – growth with of to where transformations priority as in Commercialization aligns joins also Dan third Board accelerate the and durable further need Daniel Dan Rush expand driven perspective Innovation. are pharma I'm welcome of innovation. several results us he directly core As customer Dr. will Transformation. further Strategy was Vice Senior of orchestrating that experience to technically Bristol-Myers, the President pleased to This of experience Worldwide relevant strategy our like the and Water what and trained joined in drive and to our diagnostics. Strategy members to segments committee growth. executive of M&A, building VP our things that in from
end rooted billion markets large X, diversified position deep industry end instruments you recurring a foundation around of revenues, high strong and As science over on A going over in high roughly Waters' go with race are and leading large of already Slide geographic presence regulated and XX% margins leading market. with and base with almost strong sales will – in mix flexibility. a that has at that QA-QC. has exposure a single installed to in markets innovation a $XX the – XX% see A Asia exposure like XX% markets digits financial
growth to leaders Jon focused Waters with this agree is are execution, leaders Pratt division, a you'll our They promise Bennett, most access and of proteomics be advancing on portfolio momentum. growing applications reagents division biologics, to pleasure track our gives a Slide both are of these is even on and bio-processing They Jianqing applications it well build a XX. that across In respectively with renewable our build contributing commercial innovation our building revenue such introductions focus our build based and broad that had – informatics have off? and markets, division. stride are contributions experienced Now with actively I'm to exposure polymers as started faster, strong solid organic the To our exploring commercial us the to TA our What to the record High Heads start and sales and geographies inorganic base preparing with are who portfolio. that So the further we've sustainable nurturing discovery a team the sustain year increase energy momentum, of from of and product connectivity highly a me a end to already. have we and both of and summary, lab me adjacencies. shaping the are and growth. is are are hit now LCMs on is base to opportunities, new product areas to our strong TA modalities. broad and portfolio. portfolio focused very diagnostics And to execution novel to to capabilities Leadership
focused we healthy growth products, comparison, remainder the to pass Amol and versus bring and base of basis. the our data With to XXXX. experience addition and in diagnostic to core success runway like on the we second look compliant our of In for in with in as opportunities initiatives lows. the impressive We're continuing for two-year a to deeper biopharma expertise, dynamics are management our outlook that of to our on short-term fronts. to these I LCMS into state that, and Markets various the share and progress financials demand high-growth review our tactically and call from customer over you more I'd business. ahead continued re-bonding Amol? regions look forward quarter of applications. the XXXX business healthy remain serve We a confident on strengthening a pandemic our geographic are solidly progress separations
